



US 20210284967A1

(19) **United States**(12) **Patent Application Publication**
RETTING et al.(10) **Pub. No.: US 2021/0284967 A1**(43) **Pub. Date: Sep. 16, 2021**(54) **ENGINEERED INTESTINAL TISSUE AND
USES THEREOF**(71) Applicant: **Organovo, Inc.**, San Diego, CA (US)(72) Inventors: **Kelsey Nicole RETTING**, San Diego,
CA (US); **Deborah Lynn Greene**
NGUYEN, San Diego, CA (US);
Lauran MADDEN, San Diego, CA
(US)(21) Appl. No.: **16/349,109**(22) PCT Filed: **Nov. 10, 2017**(86) PCT No.: **PCT/US2017/061016**

§ 371 (c)(1),

(2) Date: **May 10, 2019****Related U.S. Application Data**(60) Provisional application No. 62/420,024, filed on Nov.
10, 2016.**Publication Classification**(51) **Int. Cl.****C12N 5/071** (2006.01)**A61K 35/15** (2006.01)**G01N 33/50** (2006.01)(52) **U.S. Cl.**CPC **C12N 5/0679** (2013.01); **A61K 35/15**
(2013.01); **G01N 33/5088** (2013.01); **C12N**
2502/1335 (2013.01); **C12N 2535/00**
(2013.01); **C12N 2513/00** (2013.01); **C12N**
2533/30 (2013.01); **C12N 2533/54** (2013.01);
C12N 2502/23 (2013.01)

(57)

ABSTRACT

Disclosed are methods of assessing the ability of a candidate therapeutic agent to reverse, reduce or prevent intestinal injury by a potential toxic agent using a three-dimensional, engineered, bioprinted, biological intestinal tissue model. Also disclosed are methods of assessing the effect of an agent on intestinal function, the method comprising contacting the agent with a three-dimensional, engineered, bioprinted, biological intestinal tissue model.

